KW 2449

Confirm delete?

KW 2449

Zoom

Cat No: 22207

Biochemicals - Kinase Inhibitors

KW 2449 is a potent multi-kinase inhibitor of fml-like tyrosine kinase 3 (FLT3), Abelson tyrosine-protein kinase 1 (ABL), ABL-T315I, and Aurora kinase (IC50s = 6.6, 14, 4, and 48 nM, respectively).{40201} It has growth inhibitory activity against leuk...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

[4-[2-(1H-indazol-3-yl)ethenyl]phenyl]-1-piperazinyl-methanone

Correlated keywords:

KW2449 FLT-3 ABLT3151 Signal transducer activator transcription 5 MOLM13 STAT

Product Overview:
KW 2449 is a potent multi-kinase inhibitor of fml-like tyrosine kinase 3 (FLT3), Abelson tyrosine-protein kinase 1 (ABL), ABL-T315I, and Aurora kinase (IC50s = 6.6, 14, 4, and 48 nM, respectively).{40201} It has growth inhibitory activity against leukemia cells expressing FLT3 with activating mutations (GI50s = 11-46 nM) and suppresses phosphorylation of FLT3 and STAT5 in MOLM-13 cells in a dose-dependent manner in vitro. KW 2499 (100 nM) inhibits colony formation of human primary acute myeloid leukemia (AML) cells with wild-type or activated mutant FLT3. It also induces MOLM-13 xenograft regression in a dose-dependent manner in vivo. Formulations containing KW 2499 are being investigated in clinical trials for treatment of relapsed or refractory AML.

Size	5 mg
Shipping	dry ice
CAS Number	1000669-72-6
Molecular Formula	C₂₀H₂₀N₄O
SMILES	O=C(C1=CC=C(/C=C/C2=NNC3=C2C=CC=C3)C=C1)N4CCNCC4
Molecular Weight	332,4
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2933.59
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.